Prospective study of blood-based biomarkers and 20-year risk of clinically diagnosed Alzheimer's disease
Littlejohns, T.; Liu, W.; Maronga, C.; Tong, T. Y.; Amin, N.; Breeur, M.; Collister, J.; Parsaeian, M.; Papier, K.; Piazza, P.; Rockett, G.; Smith-Byrne, K.; Travis, R.; van Duijn, C.; Hunter, D.
Show abstract
Identifying individuals in the preclinical stages of Alzheimers disease (AD) is necessary for inclusion into future prevention trials. AD pathology occurs in the brain 20 or more years before diagnosis. In a nested 1:1 matched case-control sample of 426 participants selected from 19,500 members of the EPIC-Oxford cohort, we found that higher blood-based brain-derived and total p-tau 181, 217, and 231, as well as GFAP, were associated with AD over up to 25 years of follow-up (median=19.4, interquartile range 16.8-21.9 years). Of these seven biomarkers, LASSO regression selected brain-derived p-tau 217 as the strongest discriminator of AD cases from controls. The AUC for brain-derived p-tau 217 accounting for age, sex, and time of blood draw was 0.80, which increased to 0.82, 0.83, 0.84, after further addition of 1) APOE-e4 carrier status, 2) sociodemographic and lifestyle factors, and 3) both, respectively. Blood-based biomarkers, including the novel brain-derived p-tau 217, could identify individuals at-risk of AD two decades pre-diagnosis.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The ratio of plasma pTau181 and pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis 96%
- Rates of regional tau accumulation in ageing and across the Alzheimer’s disease continuum: An AIBL 18 F-MK6240 PET study 93%
- Prediction of brain age using structural magnetic resonance imaging: A comparison of clinical validity of publicly available software packages 92%
Similar papers in this journal
- Liver-specific polygenic risk score is more strongly associated than genome-wide score with Alzheimer’s disease diagnosis in a case-control analysis 96%
- Inferring Alzheimer’s disease pathologic traits from clinical measures in living adults 94%
- Examining a Preclinical Alzheimer’s Cognitive Composite for Telehealth Administration, the tPACC, for Reliability between In-Person and Remote Cognitive Testing with Neuroimaging Biomarkers 94%
Similar papers in this journal
- Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly 96%
- The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotype 95%
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology 95%
Similar papers in this journal
- Frequency of Variants in Mendelian Alzheimer’s Disease Genes within the Alzheimer’s Disease Sequencing Project (ADSP) 96%
- Targeted Serum Metabolomic Profiling and Machine Learning Approach in Alzheimer’s Disease using the Alzheimer’s Disease Diagnostics Clinical Study (ADDIA) Cohort 95%
- Exploring the genetic heterogeneity of Alzheimer’s disease: Evidence for genetic subtypes 94%